Vapes with CBD without nicotine: CBD vapes

CBD vape - Koi CBD introduces the Koi Balance Bar, an alternative to traditional vaping with CBD. No nicotine or additives are used in this development.

With the Koi Balance Bar, Koi CBD offers an alternative to traditional vaping. This product contains no nicotine, additives, fillers, or cutting agents, making it a natural flavoring solution. The Koi Balance Bar includes 250mg of pure CBD and delivers over 6,000 puffs of relaxation. With Mesh CoilTM technology, it offers smoothness and intensity. Further, the brand provides its CBD vape in five flavors. Pia Colada Ice and Strawberry Banana Ice are among the more adventurous flavors. In addition to the adventurous flavors of Pina Colada Ice and Strawberry Banana Ice, Koi CBD offers a range of other delicious flavors for its CBD vape products. From classic options like Watermelon Green Apple Sour to unique choices like Blueberry Milkshake, their flavor provides CBD enthusiasts a diverse and enjoyable experience.

Koi CBD has provided customers with high-quality CBD, Delta-8 THC, and other cannabinoids since 2015. They take pride in manufacturing and testing their products in third-party laboratories, ensuring safety and quality. All their products are made from hemp grown and processed in the United States. Koi CBD's product range includes oils, edibles, topicals, and more. Dedicated to making CBD products accessible to everyone, they aim to provide high-quality products at a reasonable price.  

1. The Koi Balance Bar by Koi CBD introduces a nicotine-free CBD vape that offers a natural option to satisfy your taste buds.
2. Providing nicotine-free CBD vapes that appeal to health-conscious consumers, the Koi Balance Bar by Koi CBD is an alternative to traditional vaping.
3. Vaping CBD with Mesh CoilTM Technology - The Koi Balance Bar by Koi CBD utilizes Mesh CoilTM technology to offer smoothness and intensity. This technology ensures that users experience a more consistent and controlled vaping experience. The Koi Balance Bar is easy to use and portable, making it the perfect option for anyone looking for a convenient and health-conscious vaping alternative.

The implications for the industry

1. CBD Products - The Koi Balance Bar by Koi CBD caters to the wellness market's growing demand for natural alternatives derived from CBD.
2. Cannabis-based products - Companies are creating cannabis-based products, such as edibles, tinctures, and topicals, to meet as traditional medications become less effective, natural alternatives are becoming more popular.
3. Cannabis-based cosmetics - Companies are creating cannabis-based cosmetics, such as lotions, creams, and shampoos, to Ensure that natural skin care products are available to meet the growing demand.
4. Wellness - Koi Balance Bar by Koi CBD taps into the health-conscious consumer trend by offering a nicotine-free CBD vape as an alternative to traditional smoking. The Koi Balance Bar allows users to experience the benefits of CBD in a smoke-free and convenient way. The vape bars are formulated with natural ingredients and contain no nicotine, making them a safe choice for users seeking CBD's potential benefits.
5. Vaping Supplies—The Koi Balance Bar by Koi CBD is a new product in the vaping supplies industry. It provides a CBD vape option with Mesh CoilTM technology. This new technology allows for a smoother vape experience, with less resistance and more flavor. The Koi Balance Bar is also easy to use and has an adjustable airflow control. It is a great choice for those looking for a reliable and flavorful vaping experience.

There is a wide variety of substances that are taken from Cannabis sativa, including cannabis, which is widely consumed and regulated. It is primarily tetrahydrocannabinol (THC) that is psychoactive in cannabis. The other phytoconstituent of cannabis is cannabidiol (CBD), which does not cause intoxication.

Commercial products are developed using different cannabis varieties in many industries. The THC content of plant varieties like hemp is usually lower than 1%. 

There is a possibility that drug laws could be bypassed if products with high CBD and low THC content are accepted globally. Cannabis with a 1% THC threshold can be sold, possessed, and consumed in Switzerland, for instance.

It is important to assess a driver's driving-related ability to determine whether they are capable of driving safely and following traffic rules. Fatigue, medication, THC use, and alcohol consumption can all limit a driver's ability to drive safely.

If THC is detected in a driver, most countries adhere to a zero-tolerance policy, whereas other countries like Switzerland implement similar laws at two levels. Drivers who violate traffic safety rules or cause an accident can be legally penalized if their blood contains 1.5 g/L of THC.

Vaping has a higher reproducibility and bioavailability of cannabis than smoking, which is the most common manner of use. The whole blood concentration of THC can reach 4.5-6.8 ng/mL after consumption of cannabis varieties with 0.8-0.94% THC content. The serum levels of THC increased by 10.8 g/L following repeated exposure to 0.16% THC.

Considering these findings, cannabis products with low THC/CBD content raise concerns regarding their effect on driving safety. Currently, it is not possible to determine the level of THC that will potentially impair driving ability based on adequate evidence. 

An overview of the study

An individual's driving ability was assessed in this study by estimating levels of THC and CBD in blood. This study recruited healthy, licensed drivers between 18-65 years of age who were experienced smokers and had valid driving licenses. Inclusion was not permissible for participants with psychiatric or physical illnesses.

In this prospective, cross-over study, two study arms were randomized, double-blind, placebo-controlled, and double-blind. Volunteers with frequent cannabis consumption were assessed in S2, as opposed to volunteers with a single consumption of two different cannabis products. 

A volcano medic vaporizer was used to administer the same dose of interventional products to all participants. However, different interventional products were assessed, including Product 1 (300 mg of the cannabis variety Harley Quinn), Product 2 (300 mg of the cannabis variety V1 Haze), and Product 3 (300mg of placebo cannabis). Product 1 released 38 mg CBD and 1.8 mg THC, while Product 2 released 39 mg CBD and 0.6 mg THC.

Five hours after consumption, the effects of these products on driving were assessed. Participants were regularly asked to provide blood samples to estimate the concentration of THC in whole blood. Neuropsychological tests were conducted after one and three hours of consumption to evaluate driving ability.